Geron(US:GERN)2025-11-05 12:06Financial Performance - Achieved $47.2 million in net product revenue from RYTELO® in Q3 2025, a significant increase from $28.2 million in Q3 2024[8] - Product revenue for Q3 2025 reached $47.167 million, a significant increase of 67.1% compared to $28.209 million in Q3 2024[26] - Total revenues for the nine months ended September 30, 2025, were $135.866 million, up from $29.457 million in the same period of 2024, representing a growth of 360.5%[26] - Reported a net loss of $18.4 million, or $0.03 per share, compared to a net loss of $26.4 million, or $0.04 per share, for the same period in 2024[7] - The net loss for Q3 2025 was $18.428 million, an improvement from a net loss of $26.447 million in Q3 2024[26] - Basic and diluted net loss per share for Q3 2025 was $0.03, compared to $0.04 in Q3 2024[26] Expenses - Total costs and operating expenses for Q3 2025 were $61.1 million, up from $56.5 million in Q3 2024[9] - Research and development expenses increased to $21.1 million in Q3 2025 from $20.2 million in Q3 2024, primarily due to increased CMC and personnel-related expenses[10] - Research and development expenses for Q3 2025 were $21.070 million, slightly increasing from $20.153 million in Q3 2024[26] - Selling, general and administrative expenses rose to $39.0 million in Q3 2025, compared to $35.9 million in Q3 2024, driven by increased sales and marketing personnel[11] - Selling, general and administrative expenses rose to $39.001 million in Q3 2025, compared to $35.877 million in Q3 2024, reflecting an increase of 5.9%[26] Cash and Assets - As of September 30, 2025, cash and marketable securities totaled approximately $421.5 million, down from $502.9 million as of December 31, 2024[6] - Total current assets as of September 30, 2025, amounted to $522.342 million, an increase from $490.992 million as of December 31, 2024[28] - Current liabilities were $87.712 million as of September 30, 2025, slightly down from $88.298 million as of December 31, 2024[28] - Stockholders' equity decreased to $248.707 million as of September 30, 2025, from $280.320 million as of December 31, 2024[28] - Noncurrent liabilities increased to $230.963 million as of September 30, 2025, compared to $225.163 million as of December 31, 2024[28] Clinical and Commercial Developments - Demand for RYTELO decreased by 3% quarter-over-quarter, with approximately 1,150 ordering accounts, an increase of about 150 accounts from the previous quarter[5] - Completed enrollment of 320 patients in the Phase 3 IMpactMF clinical trial in September 2025, with interim analysis expected in the second half of 2026[5] - Announced the appointment of Ahmed ElNawawi as Chief Commercial Officer to enhance commercial execution and drive growth for RYTELO[14] Future Guidance - The company expects total operating expenses for fiscal year 2025 to be between $250 million and $260 million, revised from previous guidance of $270 million to $285 million[12]